{"id":"https://openalex.org/W2936645929","doi":"https://doi.org/10.12968/jprp.2019.1.4.182","title":"Sacubitril/valsartan in patients with symptomatic chronic heart failure with reduced ejection fraction","display_name":"Sacubitril/valsartan in patients with symptomatic chronic heart failure with reduced ejection fraction","publication_year":2019,"publication_date":"2019-04-02","ids":{"openalex":"https://openalex.org/W2936645929","doi":"https://doi.org/10.12968/jprp.2019.1.4.182","mag":"2936645929"},"language":"en","primary_location":{"id":"doi:10.12968/jprp.2019.1.4.182","doi":"https://doi.org/10.12968/jprp.2019.1.4.182","is_oa":false,"landing_page_url":"https://doi.org/10.12968/jprp.2019.1.4.182","pdf_url":null,"source":{"id":"https://openalex.org/S4210192471","display_name":"Journal of Prescribing Practice","issn_l":"2631-8385","issn":["2631-8385","2631-8393"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["norway-1","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4322632787","host_organization_name":"Mark Allen Group","host_organization_lineage":["https://openalex.org/P4322632787"],"host_organization_lineage_names":["Mark Allen Group"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Prescribing Practice","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"green","oa_url":"https://research.birmingham.ac.uk/en/publications/608a72d8-5df9-429a-bebc-7c819696ebbe","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5042407608","display_name":"Zahraa Jalal","orcid":"https://orcid.org/0000-0002-6126-3379","observed_orcids":["https://orcid.org/0000-0002-6126-3379"]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Zahraa Jalal","raw_affiliation_strings":["Lecturer in Clinical Pharmacy and Therapeutics, School of Pharmacy, University of Birmingham"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lecturer in Clinical Pharmacy and Therapeutics, School of Pharmacy, University of Birmingham","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044349512","display_name":"Summaya Cabdi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Summaya Cabdi","raw_affiliation_strings":["Pre-registration Pharmacist, School of Pharmacy, University of Birmingham"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pre-registration Pharmacist, School of Pharmacy, University of Birmingham","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087626274","display_name":"Nazish Khan","orcid":"https://orcid.org/0000-0003-4483-7390","observed_orcids":["https://orcid.org/0000-0003-4483-7390"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nazish Khan","raw_affiliation_strings":["Principal Pharmacist Cardiac Services, West Midlands Cardiac Services Pharmacists Group, Birmingham"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Principal Pharmacist Cardiac Services, West Midlands Cardiac Services Pharmacists Group, Birmingham","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001153674","display_name":"Marina Dorsch","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Marina Dorsch","raw_affiliation_strings":["Project Manager Product Development, School of Pharmacy, University of Birmingham"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Project Manager Product Development, School of Pharmacy, University of Birmingham","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112491905","display_name":"Navneet Gill","orcid":"https://orcid.org/0009-0004-3842-5175","observed_orcids":["https://orcid.org/0009-0004-3842-5175"]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Navneet Gill","raw_affiliation_strings":["Academic Practitioner Pharmacist, School of Pharmacy, University of Birmingham"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Academic Practitioner Pharmacist, School of Pharmacy, University of Birmingham","institution_ids":["https://openalex.org/I79619799"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050667042","display_name":"Fionnuala Stalker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Fionnuala Stalker","raw_affiliation_strings":["Lead Pharmacist Cardiology and Cardiothoracic Services, West Midlands Cardiac Services Pharmacists Group, Birmingham"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lead Pharmacist Cardiology and Cardiothoracic Services, West Midlands Cardiac Services Pharmacists Group, Birmingham","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5021438499","display_name":"Alan M. Jones","orcid":"https://orcid.org/0000-0002-3897-5626","observed_orcids":["https://orcid.org/0000-0002-3897-5626"]},"institutions":[{"id":"https://openalex.org/I79619799","display_name":"University of Birmingham","ror":"https://ror.org/03angcq70","country_code":"GB","type":"education","lineage":["https://openalex.org/I79619799"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Alan M Jones","raw_affiliation_strings":["Lecturer in Medicinal Chemistry, School of Pharmacy, University of Birmingham"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lecturer in Medicinal Chemistry, School of Pharmacy, University of Birmingham","institution_ids":["https://openalex.org/I79619799"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.7197,"has_fulltext":true,"cited_by_count":5,"citation_normalized_percentile":{"value":0.73212493,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":95},"biblio":{"volume":"1","issue":"4","first_page":"182","last_page":"192"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10198","display_name":"Heart Failure Treatment and Management","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13381","display_name":"Heart rate and cardiovascular health","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10144","display_name":"Blood Pressure and Hypertension Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/sacubitril-valsartan","display_name":"sacubitril/valsartan","score":1.0},{"id":"https://openalex.org/keywords/chronic-heart-failure-with-reduced-ejection-fraction","display_name":"chronic heart failure with reduced ejection fraction","score":0.9639999866485596},{"id":"https://openalex.org/keywords/guideline-adherence","display_name":"guideline adherence","score":0.8379999995231628},{"id":"https://openalex.org/keywords/prescribing-patterns","display_name":"prescribing patterns","score":0.6589999794960022},{"id":"https://openalex.org/keywords/nice-guidance","display_name":"NICE guidelines","score":0.8410000205039978},{"id":"https://openalex.org/keywords/ace-inhibitors","display_name":"ACE inhibitors","score":0.9010000228881836},{"id":"https://openalex.org/keywords/angiotensin-receptor-blockers","display_name":"angiotensin receptor blockers","score":0.9940000176429749},{"id":"https://openalex.org/keywords/sex-differences-in-prescribing","display_name":"sex differences in prescribing","score":0.7099999785423279}],"concepts":[{"id":"https://openalex.org/C2775999527","wikidata":"https://www.wikidata.org/wiki/Q17811448","display_name":"Sacubitril, Valsartan","level":4,"score":0.9602884650230408},{"id":"https://openalex.org/C2776754050","wikidata":"https://www.wikidata.org/wiki/Q17811448","display_name":"Sacubitril","level":4,"score":0.9416428804397583},{"id":"https://openalex.org/C2777387769","wikidata":"https://www.wikidata.org/wiki/Q155472","display_name":"Valsartan","level":3,"score":0.9253125786781311},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8362358808517456},{"id":"https://openalex.org/C78085059","wikidata":"https://www.wikidata.org/wiki/Q641303","display_name":"Ejection fraction","level":3,"score":0.7560646533966064},{"id":"https://openalex.org/C2779256446","wikidata":"https://www.wikidata.org/wiki/Q33959","display_name":"Nice","level":2,"score":0.5977936387062073},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5967774391174316},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.5701387524604797},{"id":"https://openalex.org/C164705383","wikidata":"https://www.wikidata.org/wiki/Q10379","display_name":"Cardiology","level":1,"score":0.4959157407283783},{"id":"https://openalex.org/C84393581","wikidata":"https://www.wikidata.org/wiki/Q82642","display_name":"Blood pressure","level":2,"score":0.12141230702400208},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.0},{"id":"https://openalex.org/C199360897","wikidata":"https://www.wikidata.org/wiki/Q9143","display_name":"Programming language","level":1,"score":0.0}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.12968/jprp.2019.1.4.182","doi":"https://doi.org/10.12968/jprp.2019.1.4.182","is_oa":false,"landing_page_url":"https://doi.org/10.12968/jprp.2019.1.4.182","pdf_url":null,"source":{"id":"https://openalex.org/S4210192471","display_name":"Journal of Prescribing Practice","issn_l":"2631-8385","issn":["2631-8385","2631-8393"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":["norway-1","poland-20","russia-white-list-4"],"host_organization":"https://openalex.org/P4322632787","host_organization_name":"Mark Allen Group","host_organization_lineage":["https://openalex.org/P4322632787"],"host_organization_lineage_names":["Mark Allen Group"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Prescribing Practice","raw_type":"journal-article"},{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/608a72d8-5df9-429a-bebc-7c819696ebbe","doi":null,"is_oa":true,"landing_page_url":"https://research.birmingham.ac.uk/en/publications/608a72d8-5df9-429a-bebc-7c819696ebbe","pdf_url":null,"source":{"id":"https://openalex.org/S4306402634","display_name":"University of Birmingham Research Portal (University of Birmingham)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79619799","host_organization_name":"University of Birmingham","host_organization_lineage":["https://openalex.org/I79619799"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Jalal, Z, Cabdi, S, Khan, N, Dorsch, M, Gill, N K, Toner, F & Jones, A M 2019, 'Sacubitril/Valsartan (EntrestoTM) hospital prescribing in patients with symptomatic chronic HF with reduced ejection fraction : a UK multi-centre study', Journal of Prescribing Practice , vol. 1, no. 4, pp. 182-192. https://doi.org/10.12968/jprp.2019.1.4.182","raw_type":"article"}],"best_oa_location":{"id":"pmh:oai:pure.atira.dk:openaire_cris_publications/608a72d8-5df9-429a-bebc-7c819696ebbe","doi":null,"is_oa":true,"landing_page_url":"https://research.birmingham.ac.uk/en/publications/608a72d8-5df9-429a-bebc-7c819696ebbe","pdf_url":null,"source":{"id":"https://openalex.org/S4306402634","display_name":"University of Birmingham Research Portal (University of Birmingham)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I79619799","host_organization_name":"University of Birmingham","host_organization_lineage":["https://openalex.org/I79619799"],"host_organization_lineage_names":[],"type":"repository"},"license":"other-oa","license_id":"https://openalex.org/licenses/other-oa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Jalal, Z, Cabdi, S, Khan, N, Dorsch, M, Gill, N K, Toner, F & Jones, A M 2019, 'Sacubitril/Valsartan (EntrestoTM) hospital prescribing in patients with symptomatic chronic HF with reduced ejection fraction : a UK multi-centre study', Journal of Prescribing Practice , vol. 1, no. 4, pp. 182-192. https://doi.org/10.12968/jprp.2019.1.4.182","raw_type":"article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W1898188068","https://openalex.org/W2004324844","https://openalex.org/W2010663269","https://openalex.org/W2015370906","https://openalex.org/W2045719290","https://openalex.org/W2062608369","https://openalex.org/W2075860162","https://openalex.org/W2113698123","https://openalex.org/W2122972851","https://openalex.org/W2133132829","https://openalex.org/W2167666858","https://openalex.org/W2288736430","https://openalex.org/W2322644991","https://openalex.org/W2338109770","https://openalex.org/W2397911846","https://openalex.org/W2427094903","https://openalex.org/W2431563169","https://openalex.org/W2589083711","https://openalex.org/W2617849238","https://openalex.org/W2622149047","https://openalex.org/W2796480036","https://openalex.org/W2804421593","https://openalex.org/W4250417644"],"related_works":["https://openalex.org/W2890936859","https://openalex.org/W3213620301","https://openalex.org/W2921632959","https://openalex.org/W2890473667","https://openalex.org/W2736744813","https://openalex.org/W2917409149","https://openalex.org/W3046230348","https://openalex.org/W4401842235","https://openalex.org/W4293230158","https://openalex.org/W3082444387"],"abstract_inverted_index":{"Background:":[0],"Sacubitril/valsartan":[1],"is":[2],"a":[3,95,108],"combination":[4],"drug":[5],"therapy":[6,168],"for":[7,33,87],"heart":[8],"failure":[9],"(HF)":[10],"patients":[11,35,68,93,165,235],"that":[12],"has":[13],"been":[14],"shown":[15],"to":[16,84,159,197,227],"reduce":[17],"mortality":[18],"and":[19,135,143,219],"hospitalisation.":[20],"Aims:":[21],"To":[22],"explore":[23],"clinically":[24],"relevant":[25],"real-life":[26],"patient":[27],"data":[28],"regarding":[29],"prescribing":[30,174,189,202,230],"of":[31,63,81,92,102,113,133,149,164,175,190,221,223,231],"sacubitril/valsartan":[32,152,176,191,224,232],"HF":[34,67],"in":[36,39,49,56,75],"three":[37,50,139,179],"hospitals,":[38],"accordance":[40],"with":[41,69,89,209,233],"national":[42],"guidelines.":[43],"Methods:":[44],"A":[45,61,78],"retrospective":[46],"multicentre":[47],"study":[48],"large":[51],"UK":[52],"hospital":[53],"Trusts":[54,194],"based":[55],"the":[57,76,138,167,178,193,201,210,217,229,240],"West":[58],"Midlands.":[59],"Findings:":[60],"total":[62],"118":[64],"symptomatic":[65],"chronic":[66],"reduced":[70],"ejection":[71,111],"fraction":[72,112],"were":[73,169],"included":[74],"study.":[77],"high":[79],"proportion":[80,148],"prescribers":[82],"adhered":[83,196],"NICE":[85,198,211],"guidelines":[86],"treatment":[88],"sacubitril/valsartan;":[90],"99%":[91],"had":[94,107],"New":[96],"York":[97],"Heart":[98],"Association":[99],"functional":[100],"class":[101],"at":[103,137,177,192],"least":[104],"II;":[105],"82%":[106],"left":[109],"ventricle":[110],"under":[114],"35%;":[115],"100%":[116],"received":[117],"an":[118],"angiotensin-converting":[119],"enzyme":[120],"inhibitor":[121],"or":[122],"angiotensin":[123],"II":[124],"receptor":[125],"blocker":[126],"before":[127],"commencing":[128],"sacubitril/valsartan.":[129],"The":[130,147,162,188],"mean":[131],"age":[132],"men":[134,150],"women":[136],"hospitals":[140,180],"was":[141,153,181,204],"65":[142],"59":[144],"years,":[145],"respectively.":[146,161],"prescribed":[151],"greater":[154],"than":[155,185,206],"women:":[156],"80%":[157],"compared":[158,208],"20%,":[160],"majority":[163],"on":[166],"white":[170],"British":[171],"(65%).":[172],"Total":[173],"295":[182],"patients,":[183],"lower":[184,205],"expected.":[186],"Conclusion:":[187],"generally":[195],"guidance;":[199],"however,":[200],"rate":[203],"expected":[207],"resource":[212],"tool.":[213],"Further":[214],"investigations":[215],"into":[216],"safety":[218],"scope":[220],"application":[222],"are":[225],"required":[226],"match":[228],"eligible":[234],"who":[236],"could":[237],"benefit":[238],"from":[239],"medication.":[241]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-01T08:54:57.152042","created_date":"2019-04-25T00:00:00"}